RECORDS ARE PUBLISHED REGULATORY ACTIONS. FIELDS THE ISSUING AUTHORITY DID NOT PUBLISH ARE MARKED AS NOT STATED, NEVER FILLED IN.
Drug Eye AfricaNational Actions, Continental Reach
Manufacturer profile

Agog Pharma Ltd., India

Every published regulatory action recorded against this manufacturer, across all African authorities Drug Eye Africa monitors. Built strictly from published regulatory decisions and nothing else.

What these numbers are. They are counts of published regulatory actions recorded on this register. They are not a finding about the company, not an allegation, and not a measure of product quality. A manufacturer appearing here has had actions published against named products by named authorities; the actions speak for themselves and each one links to its primary notice.
3
Recorded actions
1
Countries
1
Authorities
0
Class I actions recorded

Recorded actions

3 shown
ReferenceDateCtryProductBatchesActionClassSource
DEA-RW-2022-4758949629 Apr 2022RWMetronidazole Vaginal Tablets 500mg
Agog Pharma Ltd., India
T15039RecallClass IITier 1 · Regulator-published
DEA-RW-2021-4025893314 Apr 2021RWAGOMYCIN Suspension (Erythromycin Estolate Oral Suspension 125mg/5ml),
Agog Pharma Limited, India
L96013RecallClass IITier 1 · Regulator-published
DEA-RW-2019-2707851418 Jun 2019RWSilver Sulfadiazine Cream USP 1% (Agoburn),
Agog Pharma Ltd., India
K82001RecallClass IITier 1 · Regulator-published

Counts are of published regulatory actions recorded on this register. They are not a finding about the company, and this page says so.

Names as published

This profile groups 2 spellings used by the issuing authorities: Agog Pharma Ltd., India; Agog Pharma Limited, India.

Company response

No response filed. Any named company may register and publish a reply beside these records, and the invitation is logged whether or not it is answered.

How this page is built

  • Published regulator decisions only — no press reports, no allegations
  • Name matching is conservative: only corporate-form suffixes are stripped, and a name that would reduce to a single token is kept whole
  • Every action links to its primary notice